Edition:
United Kingdom

Acceleron Pharma Inc (XLRN.OQ)

XLRN.OQ on NASDAQ Stock Exchange Global Market

37.00USD
4:24pm BST
Change (% chg)

$-0.26 (-0.70%)
Prev Close
$37.26
Open
$37.02
Day's High
$37.47
Day's Low
$36.54
Volume
19,116
Avg. Vol
125,268
52-wk High
$46.51
52-wk Low
$24.48

Latest Key Developments (Source: Significant Developments)

Acceleron Pharma Q4 Loss Per Share $‍0.62​
Tuesday, 27 Feb 2018 

Feb 27 (Reuters) - Acceleron Pharma Inc ::ACCELERON REPORTS FOURTH QUARTER AND FULL YEAR 2017 OPERATING AND FINANCIAL RESULTS.‍TOP-LINE RESULTS FROM MEDALIST AND BELIEVE PHASE 3 TRIALS OF LUSPATERCEPT ARE EXPECTED IN MID-2018​.‍ON TRACK TO INITIATE A PHASE 2 TRIAL IN PULMONARY ARTERIAL HYPERTENSION IN 1H 2018​.QTRLY LOSS PER SHARE $‍0.62​.  Full Article

Acceleron plans to initiate part 2 of ACE-083 FSHD phase 2 trial during Q2 of 2018
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Acceleron Pharma Inc ::ACCELERON PHARMA INC - PLANS TO INITIATE PART 2 OF ACE-083 FSHD PHASE 2 TRIAL DURING Q2 OF 2018.ACCELERON ANNOUNCES PRELIMINARY RESULTS FROM PART 1 OF THE ACE-083 PHASE 2 TRIAL IN PATIENTS WITH FACIOSCAPULOHUMERAL DYSTROPHY.  Full Article

Acceleron Pharma qtrly net loss per share $0.65
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Acceleron Pharma Inc :Acceleron Pharma reports third quarter 2017 operational and financial results.Acceleron Pharma Inc - ‍existing cash, cash equivalents and investments will be sufficient to fund projected operating requirements into 2021​.Acceleron Pharma Inc qtrly net loss per share applicable to common stockholders basic and diluted $0.65.Q3 earnings per share view $-0.64 -- Thomson Reuters I/B/E/S.  Full Article

Acceleron announces pricing of public offering of common stock
Thursday, 21 Sep 2017 

Sept 20 (Reuters) - Acceleron Pharma Inc :Acceleron announces pricing of public offering of common stock.Acceleron Pharma - Announced underwritten public offering of 5.4 million shares of common stock at a price to public of $37 per share.  Full Article

Acceleron announces proposed public offering of common stock
Tuesday, 19 Sep 2017 

Sept 19 (Reuters) - Acceleron Pharma Inc :Acceleron announces proposed public offering of common stock.Acceleron Pharma Inc - Announced that it intends to offer and sell, subject to market and other conditions, $150 million of its common stock.Acceleron Pharma - Intends to use net proceeds from offering to conduct clinical trials and associated activities.  Full Article

Acceleron Pharma Q2 loss per share $0.77
Thursday, 3 Aug 2017 

Aug 3 (Reuters) - Acceleron Pharma Inc :Acceleron Pharma reports second quarter 2017 operational and financial results.Qtrly loss per share $0.77.Acceleron Pharma Inc - collaboration revenue for Q2 was $3.1 million..  Full Article

Acceleron announces first patient treated in phase 2 clinical trial of ACE-083
Tuesday, 1 Aug 2017 

Aug 1 (Reuters) - Acceleron Pharma Inc :Acceleron announces first patient treated in phase 2 clinical trial of ACE-083 in Charcot-Marie-Tooth disease.  Full Article

Celgene and Acceleron complete enrollment in MEDALIST, BELIEVE Phase 3 studies of luspatercept
Thursday, 1 Jun 2017 

June 1 (Reuters) - Celgene Corp :Celgene and Acceleron complete target enrollment in the medalist and believe Phase 3 studies of luspatercept in myelodysplastic syndromes and beta-thalassemia.Acceleron Pharma Inc - ‍companies expect to report top-line results from Phase 3 studies in mid-2018​.Acceleron Pharma Inc - ‍medalist phase 3 trial has enrolled 210 patients with lower-risk mds​.Acceleron Pharma Inc - ‍believe phase 3 trial has enrolled 300 patients with transfusion dependent beta-thalassemia​.  Full Article

Acceleron Pharma qtrly loss per share $0.66
Monday, 8 May 2017 

May 8 (Reuters) - Acceleron Pharma Inc :Acceleron pharma reports first quarter 2017 operational and financial results.Acceleron pharma inc - collaboration revenue for q1 was $3.7 million.Acceleron pharma inc qtrly loss per share $0.66.Acceleron pharma inc - plans to initiate luspatercept phase 3 trial in first-line, lower-risk mds in early 2018.  Full Article

Acceleron announces management change
Tuesday, 2 May 2017 

May 2 (Reuters) - Acceleron Pharma Inc ::Acceleron announces management change.Acceleron Pharma Inc - Steven Ertel, due to medical reasons, will transition from his role as executive vice president and chief operating officer.Acceleron Pharma Inc - Ertel was recently diagnosed with amyotrophic lateral sclerosis.  Full Article

BRIEF-Acceleron Pharma Q4 Loss Per Share $‍0.62​

* ACCELERON REPORTS FOURTH QUARTER AND FULL YEAR 2017 OPERATING AND FINANCIAL RESULTS